The UK and US have agreed to a important trade agreement that will preserve no duties on UK pharmaceutical exports entering the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has agreed to increase funding on medicines through the National Health Service (NHS). This pledge guarantees that tariffs on these vital goods will stay at zero for a timeframe of three years.
This agreement follows earlier threats to hike import taxes on patented pharmaceutical products, with figures mentioned as high as double the cost.
"This agreement between the UK bolsters the international landscape for new treatments and brings long-overdue equity to U.S.–U.K. medicine commerce," an announcement said.
Commercial Impact
Drugs represent one of the UK's most significant exports to the America, which is clearly the biggest buyer for large companies like GSK and AstraZeneca.
Statistics reveal that in the 12 months prior to the third quarter, the UK sold drugs worth £11.1bn to the US. This figure made up a significant portion of British export trade in that span.
"This deal secures work, stimulates funding and sets the stage for the UK to emerge as a global hub for life sciences," a minister remarked.
Specific NHS Changes
The agreement includes several notable pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it deems new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a goal to double total NHS spending on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Payback Limit: The percentage manufacturers must pay back to the NHS to prevent overspending will be capped at 15%. In the past, rebates were more than twenty percent.
Industry Background
The pact takes place against a long-running tension between the drug companies and the UK government over spending levels and NHS adoption.
These tensions were exacerbated by arguments that US customers were charged a premium for the equivalent treatments than consumers in the UK and Europe.
In recent months, several significant drug company projects in the UK have been paused or cancelled, while major expansions have been pledged toward projects in the United States.
One official acknowledged that the NHS had to spend more on drugs, noting that its spending on drugs had shrunk as a proportion of its overall budget over the past decade.
